Senaste försöken


EudraCT Number: 2023-000150-20 Sponsor Protocol Number: 1 Start Date: 2023-03-22
Sponsor Name: Bispebjerg-Frederiksberg Hospital
Full Title: The effect of exercise on pharmacodynamics and pharmacokinetics of a single dose of unfractionated heparin: A randomized, controlled, cross-over study
Medical condition: Unfractionated heparin is used for the prevention and treatment of deep vein thrombosis and complications hereof
Disease: Version SOC Term Classification Code Term Level
21.1 10047065 - Vascular disorders 10051055 Deep vein thrombosis PT
Population Age: Adults Gender: Male
Trial protocol: DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003885-19 Sponsor Protocol Number: NOT-APPLICABLE-HUFA Start Date: 2023-03-15
Sponsor Name:
Full Title: ECOGUIDED GENICULAR NERVE BLOCK IN PATIENTS WITH KNEE OSTEOARTHRITIS BY LOCAL ANESTHETIC OR BY COMBINATION OF LOCAL ANESTHETIC AND CORTICOID: PLACEBO-CONTROLLED RANDOMIZED BLIND CLINICAL TRIAL
Medical condition: KNEE OSTEOARTHRITIS
Disease: Version SOC Term Classification Code Term Level
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002593-89 Sponsor Protocol Number: TV48574-IMM-20038 Start Date: 2023-03-15
Sponsor Name: Teva Branded Pharmaceutical Products R&D, Inc.
Full Title: A 24-Week, Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy Safety, and Tolerability of TEV-48574 in Adult Patients with Moderate to Severe Ulcera...
Medical condition: Moderate to severe Ulcerative colitis or moderate to severe Crohn's disease
Disease: Version SOC Term Classification Code Term Level
20.1 100000004856 10045365 Ulcerative colitis LLT
20.0 100000004856 10011400 Crohn's colitis LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) CZ (Ongoing) HU (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-004890-29 Sponsor Protocol Number: FIT-PIV Start Date: 2023-03-09
Sponsor Name: Elgan Pharma Ltd
Full Title: A Multi-center, Double-Blind, Randomized, Two-Arm, Parallel-Group, Placebo Controlled Study to Assess the Efficacy and Safety of ELGN-2112 on Intestinal Malabsorption in Preterm Infants
Medical condition: Gastro-intestinal malabsorption due to gastro-intestinal immaturity in preterm infants.
Disease: Version SOC Term Classification Code Term Level
20.1 100000004856 10025479 Malabsorption syndrome LLT
Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
Trial protocol: FR (Ongoing) ES (Ongoing) NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005066-17 Sponsor Protocol Number: CADPT09A12201 Start Date: 2023-03-07
Sponsor Name: Novartis Pharma AG
Full Title: A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants w...
Medical condition: Idiopathic pulmonary fibrosis
Disease: Version SOC Term Classification Code Term Level
21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10021240 Idiopathic pulmonary fibrosis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-001384-27 Sponsor Protocol Number: 2022-031 Start Date: 2023-02-28
Sponsor Name: Franciscus Gasthuis & Vlietland
Full Title: Peroperative Administration of Tranexamic acid in Roux-en-Y and one-anastomosis gastric bypass to reduce hemorrhage rates (PATRY study): a randomized controlled trial
Medical condition: Morbid obesity
Disease: Version SOC Term Classification Code Term Level
21.1 100000004865 10059610 Obesity surgery LLT
21.0 100000004861 10027966 Morbid obesity LLT
21.1 100000004865 10068900 Bariatric surgery LLT
Population Age: Adults Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002833-33 Sponsor Protocol Number: APL2-C3G-314 Start Date: 2023-02-22
Sponsor Name: Apellis Pharmaceuticals, Inc.
Full Title: An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferati...
Medical condition: C3 glomerulopathy (C3G) or immune complex membranoproliferative glomerulonephritis (IC-MPGN)
Disease: Version SOC Term Classification Code Term Level
20.0 10038359 - Renal and urinary disorders 10038359 Renal and urinary disorders SOC
20.0 10038359 - Renal and urinary disorders 10077827 C3 glomerulopathy PT
21.1 10038359 - Renal and urinary disorders 10027168 Membranoproliferative glomerulonephritis LLT
Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) CZ (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-003314-39 Sponsor Protocol Number: 78934804CRD2001 Start Date: 2023-02-21
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
Medical condition: Moderately to Severely Active Crohn's Disease
Disease: Version SOC Term Classification Code Term Level
20.0 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing) NL (Ongoing) CZ (Ongoing) PT (Ongoing) BG (Ongoing) NO (Ongoing) SI (Ongoing) SE (Ongoing) DK (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-002680-30 Sponsor Protocol Number: D926XC00001 Start Date: 2023-02-20
Sponsor Name: AstraZeneca AB
Full Title: A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator’s Choice of Therapy in Patients With Stage I-III Triple-negative Breast Can...
Medical condition: Stage I-III triple-negative breast cancer with residual invasive disease after neoadjuvant therapy.
Disease: Version SOC Term Classification Code Term Level
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: ES (Ongoing) DE (Ongoing) DK (Ongoing)
Trial results: (No results available)

EudraCT Number: 2021-005528-39 Sponsor Protocol Number: 78934804UCO2001 Start Date: 2023-02-16
Sponsor Name: Janssen-Cilag International NV
Full Title: A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy with Gusel...
Medical condition: Moderately to Severely Active Ulcerative Colitis
Disease: Version SOC Term Classification Code Term Level
20.1 100000004856 10045365 Ulcerative colitis LLT
Population Age: Adults Gender: Male, Female
Trial protocol: DE (Ongoing) ES (Ongoing) HU (Ongoing) CZ (Ongoing) NL (Ongoing) SK (Ongoing) BG (Ongoing) NO (Ongoing) DK (Ongoing) SE (Ongoing) SI (Ongoing)
Trial results: (No results available)